



Express Mail No.: **EV 473 971 651 US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: SRIVASTAVA *et al.*

Confirmation No.: 3088

Serial No.: 09/393,652

Art Unit: 1644

Filed: September 10, 1999

Examiner: Gerald R. Ewoldt, Ph.D.

For: METHODS AND COMPOSITIONS FOR THE
TREATMENT AND PREVENTION OF GRAFT
REJECTION USING HEAT SHOCK PROTEINS

Attorney Docket No.: 8449-025-999

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.56 AND § 1.97**

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the continuing duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references **CX-DC** listed on the attached form entitled "List of References Cited by Applicant."

Copies of references **CY-DC** are submitted herewith. A copy of reference **CX** is not submitted herewith because it is a U.S. patent. Pursuant to 37 C.F.R. § 1.98 (a)(2)(i) as amended (*see* Fed. Reg. vol. 69, no. 182, Sept. 21, 2004), the requirement for providing a copy of each U.S. patent or U.S. patent application publication listed in an Information Disclosure Statement in a patent application, regardless of the filing date of the application, is eliminated.

02/01/2007 TTRAN1 00000004 503013 09393652

02 FC:1806 180.00 DA

NYI-3951154v1

Identification of the listed references is not meant to be construed as an admission by Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c), Applicants believe that a fee of \$180.00 is due in connection with the filing of this Supplemental Information Disclosure Statement. Please charge the amount of any required fee to Jones Day deposit account no. 50-3013.

Date: January 29, 2007

Respectfully submitted, *By: [Signature]*
T.C. TSANG 40,258
Adriane M. Antler 32,605
Adriane M. Antler (Reg. No.)

JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Express Mail No.: **EV 473 971 651 US**

Sheet 1 of 1 of List of References

Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

8449-025-999

APPLICATION NO.

09/393,652

APPLICANT

Srivastava et al.

FILING DATE

September 10, 1999

ART UNIT

1644

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	CX	US 6,017,540	1/25/00	Srivastava	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	CY	BEN-YEHUDA et al., 2003, "Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents," Vaccine 21(23):3169-78
	CZ	MAZZAFERRO et al., 2003, "Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer," Clin. Cancer Res. 9(9):3235-45
	DA	SATO et al., 2001, "Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice," Blood 98(6):1852-7
	DB	TAMURA et al., 1997, "Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations," Science 278(5335):117-20
	DC	YEDAVELLI et al., 1999, "Preventive and therapeutic effect of tumor derived heat shock protein, gp96, in an experimental prostate cancer model," Int. J. Mol. Med. 4(3):243-8

EXAMINER
NYI-3951160v1**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.